Spatiotemporal analysis of breast cancer hospitalizations in Portugal in 2002–2016 by Gomes, Inês et al.
Research Article
Port J Public Health 2020;38:6–14
Spatiotemporal Analysis of Breast 
Cancer Hospitalizations in Portugal in 
2002–2016
Inês Afonso Gomes a–c    Bruno Moita a, d    Carla Nunes a, c    
a
 Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Lisboa, Portugal; b Pfizer, Porto Salvo, Portugal; 
c
 Centro de Investigação em Saúde Pública (CISP), Universidade Nova de Lisboa, Lisboa, Portugal; d Centro Hospitalar 
Universitário do Algarve, Faro, Portugal
Received: March 1, 2020
Accepted: May 11, 2020
Published online: July 13, 2020
Inês Afonso Gomes




© 2020 The Author(s). Published by S. Karger AG, Basel 





Breast neoplasms · Spatiotemporal analysis · 
Hospitalization · Portugal
Abstract
Introduction: Breast cancer (BC) is the most common cancer 
among Portuguese women and it is associated with high 
hospitalization rates. Therefore, this study aims to character-
ize the BC hospital admission rate (HAR) in women in the 
period of 2002–2016, with an additional focus on spatiotem-
poral patterns of hospitalizations by BC (main code). Meth-
ods: After a descriptive analysis of all BC hospitalizations, the 
main BC code HAR was studied using mapping techniques, 
analysis of spatiotemporal clusters, and analysis of spatial 
variations in temporal trends. Results: The BC-HAR was 
118.72/105 women, showing a growth of 3.109% per year in 
this period. The median length of stay (LOS) in these patients 
was 5 days, and most cases were programmed surgical ad-
missions. Several spatiotemporal clusters and spatial varia-
tions in temporal trends were detected. The seaside area of 
the country showed 4 high HAR clusters in the spatiotempo-
ral analysis. Additionally, the seaside north of the country 
and 2 isolated counties presented significantly different 
temporal trends in BC-HAR versus the rest of the country. 
These clusters suggest regional asymmetries, as they showed 
differences in terms of: demographic characteristics (age at 
admission and rurality of county of residence), the type of 
admission, LOS, and outcomes of hospitalization. Conclu-
sion: This study identified key areas of high BC-HAR and in-
creasing trends for female HAR, providing evidence of spa-
tial heterogeneities in this health indicator.
© 2020 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
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Resumo
Introdução: O cancro da mama é a neoplasia mais co-
mum em mulheres Portuguesas e é responsável por el-
evadas taxas de hospitalização. Como tal, este estudo pre-
tende caracterizar as admissões hospitalares por cancro 
da mama feminino no período de 2002–2016, com foco 
adicional nos padrões espácio-temporais das hospitaliza-
ções por cancro da mama (código principal). Métodos: 
Após uma análise descritiva de todas as hospitalizações 
com código de cancro da mama, os internamentos com 
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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código principal para esta patologia foram estudados 
com recurso a técnicas de mapeamento, análise de clus-
ters espácio-temporais e variações espaciais em tendên-
cias temporais. Resultados: A taxa de internamento hos-
pitalar por cancro da mama foi 118.72/105 mulheres, 
mostrando um crescimento de 3.109%/ano neste perío-
do. A mediana do tempo de hospitalização nestas doen-
tes foi 5 dias, e a maioria dos internamentos correspon-
deram a admissões cirúrgicas programadas. Vários clus-
ters espácio-temporais e variações espaciais em tendências 
temporais foram detetados. A zona costeira do país apre-
sentou 4 clusters com elevada taxa de internamento hos-
pitalar na análise espácio-temporal. Adicionalmente, a 
zona norte costeira e 2 concelhos isolados exibiram 
tendências temporais significativamente diferentes das 
descritas no resto do país. Estes clusters sugerem assime-
trias regionais, apresentando divergências nas caracter-
ísticas demográficas (idade de admissão e ruralidade do 
concelho de residência), tipo de admissão, tempo de in-
ternamento e outcome da hospitalização. Conclusão: Este 
estudo identificou áreas chave de elevada taxa de inter-
namento hospitalar por cancro da mama e uma tendência 
crescente nestes internamentos, fornecendo dados sobre 
a heterogeneidade espacial neste indicador de saúde.
© 2020 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
Introduction
Breast cancer (BC) is the most frequent malignant dis-
ease in women and it represents a large disease burden, 
being a major cause of cancer-associated hospital dis-
charges in European women and numerous hospital ad-
missions [1–5]. Several studies have indicated that the ma-
jority of hospital admissions in BC patients are due to ma-
jor surgeries and that the number of hospitalizations in 
these patients are associated with the presence of comor-
bidities and the stage of the disease [6–12]. Furthermore, 
a study conducted in 2002–2004 in Spain showed a differ-
ential BC hospital admission rate (HAR) in different areas 
due to older age and local variation in BC incidence [5].
The median hospital length of stay (LOS) in BC pa-
tients varies according to the studies considered, ranging 
from 1.7 to 14.5 days [5, 6, 8, 12–17]. Additionally, the 
LOS of BC patients has been associated with the stage at 
diagnosis, the presence of comorbidities, deprivation, 
age, surgical procedure, and year of analysis (6 and 5 days 
in 1996 and 2006, respectively, and 5 and 4 days in 
1997/1998 and 2004/2005, respectively) [14, 15, 17–21].
The published literature indicates that the BC-associ-
ated hospital production and the number of surgeries for 
BC management have been increasing in the last decade 
in Portugal [3, 22–24] (online suppl. Table 1, 2; see www.
karger.com/doi/10.1159/000508634 for all online suppl. 
material). Another publication pointed that, in the period 
of 2000 to 2008, BC was responsible for 9.5–9.7% of hos-
pitalizations and 3.6–5.6% of deaths during hospitaliza-
tion in cancer patients [24]. The majority of hospitaliza-
tions in BC patients described in this study were women 
aged 45–64 years, and regional asymmetries were report-
ed both in hospitalization and in-patient deaths [24].
The monitoring of hospitalizations, i.e., regional dif-
ferences and trend variations, can provide powerful in-
sights for the assessment/setting of public health policies, 
estimation of the burden and status of health conditions, 
and planning of resource allocation [4, 25–27]. Differ-
ences in hospital procedures, treatment patterns, and 
outpatient resources might lead to regional differences in 
hospitalization lengths among different areas [14]. The 
analysis of discharged BC patients can also be a useful tool 
for monitoring the burden of the disease/patterns at na-
tional and local levels [26].
Therefore, the main goal of this study was to describe 
the female hospitalizations related to BC (both main and 
secondary causes of admission) and conduct a spatiotem-
poral analysis of main BC admission hospitalizations be-
tween 2002 and 2016 in Portugal. Additionally, a charac-
terization of the spatiotemporal patterns of female BC 
hospitalizations and assessment of the differences in the 
clusters identified were conducted in this study.
Methods
Data and Sources
The hospital admissions of female patients with BC (codes 
174.0–174.9 of the ICD 9) in 2002–2016 were obtained from the 
hospital morbidity database (BDMH). After exclusion of same-day 
admissions, both patients with main (n = 100,148) and secondary 
(n = 36,459) BC admission codes (up to a maximum of 20 diagno-
sis codes) were included in this study in order to have complete 
assessment of the burden of this disease in hospital production 
[5–9, 12–16, 24–31]. This database, containing all of the admis-
sions occurring in national healthcare service (SNS) Portuguese 
mainland hospitals, was obtained from the Administração Central 
do Sistema de Saúde (ACSS) and had been previously anonymized. 
The median female population per county/year and the median 
population density was calculated from data freely available at Sta-
tistics Portugal [32].
Methods
Firstly, a descriptive analysis of BC hospital admissions was 
done for patients with main and secondary BC admission informa-
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tion (i.e., year of admission, LOS, destination after discharge, type 
of admission, age at admission, rurality of residence county, and 
main admission code). Patients were divided into the following 4 
age groups based on the literature: < 40, 40–49, 50–64, and ≥65 
years [2, 33–43]. Patients aged ≥100 years (n = 21; 0.012%) were 
excluded from the analysis, as were patients with an LOS of 0 days 
(n = 44,779; 25.8%). 
The median population density in the period of analysis was 
calculated for each of the counties, and cut-off values of 150 and 
300 inhabitants/km2 were applied for the definition of rural, inter-
mediate, and urban areas [44]. The annual HAR was defined as the 
number of female hospitalizations with a BC admission code in a 
certain area in a determined year, divided by the median population 
(at June 30) of female inhabitants in that same area and year [45]. 
The HAR for the main and secondary and all BC admission codes 
Table 1. Baseline and hospitalization characteristics of all female BC hospital admissions in 2002–2016 in mainland Portugal
Female BC
all admission codes 
(n = 129,048)
main admission code 
(n = 100,148)
secondary admission code 
(n = 36,459)
Year of admission
2002 7,566 (5.9) 5,946 (5.9) 2,925 (8.0)
2003 7,489 (5.8) 5,900 (5.9) 2,627 (7.2)
2004 7,624 (5.9) 6,040 (6.0) 2,853 (7.8)
2005 7,518 (5.8) 6,032 (6.0) 2,483 (6.8)
2006 7,626 (5.9) 6,182 (6.2) 2,455 (6.7)
2007 7,918 (6.1) 6,237 (6.2) 2,485 (6.8)
2008 8,389 (6.5) 6,652 (6.6) 2,315 (6.3)
2009 8,589 (6.7) 6,769 (6.8) 1,995 (5.5)
2010 8,970 (7.0) 6,894 (6.9) 2,127 (5.8)
2011 9,519 (7.4) 7,433 (7.4) 2,122 (5.8)
2012 9,407 (7.3) 7,305 (7.3) 2,147 (5.9)
2013 9,911 (7.7) 7,591 (7.6) 2,369 (6.5)
2014 9,550 (7.4) 7,180 (7.2) 2,434 (6.7)
2015 9,785 (7.6) 7,273 (7.3) 2,578 (7.1)
2016 9,187 (7.1) 6,714 (6.7) 2,544 (7.0)
LOSa, days 5 (1–365) 5 (1–365) 6 (1–365)
Destination after dischargeb
Home 117,817 (91.3) 93,304 (93.2) 31,681 (86.9)
Other hospital 1,258 (1.0) 428 (0.4) 858 (2.4)
Deceased 8,649 (6.7) 5,491 (5.5) 3,501 (9.6)
Other 1,324 (1.0) 925 (0.9) 379 (1.0)
Type of admission
Programmed 91,713 (71.1) 81,368 (81.2) 17,040 (46.7)
Urgent 28,920 (22.4) 10,859 (10.8) 18,668 (51.2)
Other 8,415 (6.5) 7,930 (7.9) 751 (2.1)
Type of admission
Medical 37,851 (29.3) 14,536 (14.5) 24,366 (66.8)
Surgical 91,194 (70.7) 85,612 (85.5) 12,090 (33.2)
Age at admissionc, years 61 (0–99)/60.67±14.24 59 (0–99)/59.62±13.71 64 (0–99)/63.26±15.19
<40 years 8,427 (6.5) 6,724 (6.7) 2,222 (6.1)
40–49 years 23,259 (18.0) 19,366 (19.3) 5,402 (14.8)
50–64 years 44,770 (34.7) 36,269 (36.2) 11,203 (30.7)
≥65 years 52,592 (40.8) 37,789 (37.7) 17,632 (48.4)
Rurality of residence county
Rural ND 29,195 (29.15) ND
Intermediate ND 11,603 (11.59) ND
Urban ND 51,961 (51.88) ND
Values are presented as means ± SD, medians (range) or numbers (%). ND, not determined. a Cut-off set at 365 days. b Long-term 
hospitalization and transfer to another institution were grouped under “other hospital”, whereas “other” encompasses the remaining 
not-otherwise-classified destiny after hospital discharge. c Cut-off set at 100 years. 
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were determined (as crude rates) per year and globally (entire pe-
riod). The HAR was expressed per 105 inhabitants. Additionally, 
for patients with a main BC admission code, temporal and spatio-
temporal clusters plus the detection of spatial variations in tempo-
ral trends were identified [6, 8, 9, 12–14, 16, 24, 26, 28–30]. Patients 
without a valid residence county code (n = 7,536; 7.5%) or resident 
in the insular Madeira and Açores areas (n = 147; 1.5%) were not 
included in this analysis. This analysis was conducted using 
SaTScanTM software (version 9.4.4; Martin Kulldorff, Boston, MA, 
USA), applying circular windows with a maximum of 20% of the 
studied population and using a discrete Poisson model. The spatial 
unit used in the spatiotemporal analysis was the mainland counties 
(n = 278). The significance level was set at 0.05. The comparison 
between spatial variations in temporal trend clusters was done us-
ing a nonparametric test of median comparisons and the χ2 test for 
independency (for the remaining comparisons). Descriptive analy-
sis and statistical tests comparing the characteristics of the clusters 
identified were conducted in Statistical Package for Social Sciences 
(SPSSTM, version 22 for Windows; IBM Corp., Armonk, NY, USA), 
and the results were mapped using QGISTM software (version 2.18s; 
Free Software Foundation Inc., Boston, MA, USA). 
Results
Country Analysis
In the period between 2002 and 2016, for patients with 
a main BC admission code the malignant neoplasm of 
other specified sites of the female breast (41.9%) or of the 
upper-outer quadrant of the female breast (29.0%) were 
the most common code of admission. Admissions for ra-
diotherapy (4.1%), chemotherapy/immunotherapy (3.8%), 
fitting and adjustment of vascular catheter (2.4%), (drug-
induced) neutropenia (6.5%), secondary malignant neo-
plasms (8.8%), pneumonia (3.7%), congestive heart fail-
ure (1.5%), and urinary tract infection (1.5%) represented 
the main admission codes for patients with secondary BC 
codes. Additionally, 19.2% of the patients with a second-
ary BC code had a main BC code at admission (15.5%). 
Demographic characteristics of the patients with BC ad-
mission codes can be found in Table 1.
Although the median LOS of patients with BC as the 
main admission code was similar to that shown for all hos-
pitalizations with BC admission codes, the median age at 
admission was lower in the first group (5 days and 59 
years, respectively). Most (85.5%) of these patients were 
admitted for surgical procedures, versus 33.2% for pa-
tients with secondary BC admission codes. Furthermore, 
patients with secondary BC admission codes showed a 
higher LOS than those with a main BC admission code (6 
days). Additionally, a higher percentage of patients with 
secondary BC admission codes were admitted as urgent 
(51.2 vs. 10.8% for a main BC admission code).
Table 2. Total and annual number of main BC admission code hospitalizations and hospital admission rate (per 105 inhabitants) in Por-
tugal in the period of 2002–2016









2002 5,068 (5.47) 363.16 (Fronteira, inland; 7) 0 (11; 4.0) 101.00 92.04 66.65
2003 5,137 (5.54) 539.08 (Mourão, inland; 8) 0 (9; 3.2) 103.50 100.07 66.02
2004 5,127 (5.53) 382.30 (Monforte, inland; 7) 0 (18; 6.5) 97.41 92.55 60.44
2005 4,995 (5.39) 355.66 (Cuba, inland; 9) 0 (13; 4.7) 95.56 88.46 61.39
2006 5,123 (5.53) 443.46 (Castanheira de Pêra, inland; 8) 0 (15; 5.4) 98.55 93.88 72.21
2007 5,108 (5.51) 387.13 (Sardoal, inland; 8) 0 (14; 5.0) 99.54 91.95 67.22
2008 6,141 (6.63) 515.02 (Castanheira de Pêra, inland; 9) 0 (5; 1.8) 116.67 110.30 64.16
2009 6,596 (7.12) 359.3 (Sousel, inland; 10) 0 (6; 2.2) 124.88 116.49 62.26
2010 6,542 (7.06) 404.65 (Penamacor, inland; 12) 0 (5; 1.8) 117.66 111.19 56.63
2011 7,229 (7.80) 355.95 (Góis, inland; 8) 0 (10; 3.6) 134.37 131.65 60.87
2012 7,242 (7.82) 421.89 (Vila Nova de Poiares, inland; 16) 0 (3; 1.1) 135.68 127.26 63.58
2013 7,508 (8.10) 373.68 (Carregal do Sal, inland; 19) 0 (4; 1.4) 143.45 138.79 65.13
2014 7,102 (7.67) 372.09 (Arronches, inland; 6) 0 (4; 1.4) 134.34 129.59 59.68
2015 7,191 (7.76) 410.00 (Alfândega da Fé, inland; 10) 0 (8; 2.9) 136.81 129.64 68.30
2016 6,534 (7.05) 645.51 (Pedrogão Grande, inland; 12) 0 (8; 2.9) 123.55 114.50 71.64
Total 92,643 (100) 212.37 (Coimbra, inland; 2,425) 55.14 (Vizela, 1; 0.4) 117.53 111.96 66.62
a The names of the counties are not presented due to the high number of counties presenting the minimum hospital admission rate. 
All of the counties presenting the highest hospital admission rate were rural, except for Coimbra, which is urban. All countries without 
a coast line border were considered inland.
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Analysis by County (n = 278)
The Portuguese counties presenting the highest HAR 
for patients with a main BC admission code varied over 
time. In each of the analyzed years, 1.1–6.5% of the coun-
ties showed no hospitalizations with a main BC admis-
sion code; however, no counties presented no hospitaliza-
tions with this cancer code in the period of 2002–2016 
(Table 2). 
Spatiotemporal Analysis by Counties (n = 278)
In the period of 2002–2016 (n = 92,643), the annual fe-
male HAR for BC main admission codes was 118.72/105 
inhabitants, showing a growth of 3.109% per year. Addi-
tionally, the period of 2009–2015 showed a significantly 
higher HAR than the remaining analyzed years (135.2/105 
inhabitants, relative risk [RR] = 1.39; p = 0.001). Several sta-
tistically significant high HAR spatiotemporal clusters for 
main BC admission codes were identified and are described 
in Table 3. Additionally, details on the spatial variations in 
temporal trends clusters identified in mainland Portugal 
are further described below in Table 4 and Figure 1.
Discussion/Conclusion
To our knowledge, this study is the first spatiotempo-
ral analysis conducted on the hospitalization of BC pa-
tients, providing a basis for future studies using this 
methodology and further analysis on the BC burden 
among Portuguese women. 
Most counties showed cases of BC hospitalizations in 
the period of 2002–2016, and most of these hospital ad-
Table 3. Spatiotemporal main BC admission codes HAR high clusters in Portugal between 2002 and 2016 presenting statistical signifi-
















2010–2016 Cluster A: Porto 10,875 (41) 1.32 1.37 157.3
2011–2015 Cluster B: Braga 6,550 (30) 1.20 1.21 142.1
2010–2016 Cluster C: Lisboa-Setúbal-Alentejo 8,493 (33) 1.16 1.17 137.2
2009–2015 Cluster D: Leiria 6,653 (42) 1.10 1.11 130.6
Table 4. Characteristics of spatial variation in temporal trend clusters of main BC admission codes (clusters E, F, and G plus the rest of 







The rest of 
the mainland
Hospitalizations, N (counties, n) 16,320 (22) 47 (1) 145 (1) 76,247 (256)
Inside time/outside time trend, % +9.255/+1.885 +12.323/+3105 +8.188/+3.102 –
Annual HAR (/105 inhabitants) 105.4 150.1 124.0 –
Median age at admission (range)b, years 57 (15–99)a 67 (40–89)a 55 (24–86)a 60 (0–99)a
Median LOS (range)b, days 4 (1–164) 8 (1–44) 6 (1–69) 5 (1–365)a
Destination after discharge (home/deceased)c, % 94.39/3.36 93.62/6.38 94.48/4.83 92.93/5.90
Programmed admissionsc,d, % 87.12 89.36 86.21 80.09
Surgical admissionsc, % 90.33 87.23 86.21 84.54
Rurality (rural/urban)c, % 2.39/95.64 100/0 0/0 37.72/50.32
a Cut-off set at 100 years and 365 days, respectively. b p < 0.001 (nonparametric test of median comparisons). c p < 0.001 (χ2). d After 
grouping admission type into programmed, urgent, and other.
Spatiotemporal Analysis of BC 
Hospitalizations in Portugal in 2002–2016
11Port J Public Health 2020;38:6–14
DOI: 10.1159/000508634
missions (77.61%) presented BC as the main admission 
code. The median age at admission of patients with BC 
admission codes was 61 years, which is slightly higher 
than prior data published for Portuguese patients in 2008 
(median age: 59 years) [24]. The median LOS observed in 
this period was 5 days, which falls within the range pub-
lished for BC patients, showing a decrease from 7 days in 
2002 to < 4 days from 2010 onwards (data not shown); this 
is in agreement with previously reported data [5, 6, 8, 12–
16, 18, 46]. This decrease in LOS could be a result of di-
agnosis at earlier stages or the evolution of surgical pro-
cedures over time [14, 18, 19]. A total of 71.1% of the 
analyzed hospitalizations were programmed, and 70.7% 
of admissions corresponded to surgical interventions, 
matching the published data [6–9]. Additionally, 91.3% 
of the patients were discharged to their homes, whereas 
6.7% died during their hospital admission; this represents 
a higher hospital lethality than that previously published 
on Portuguese BC patients (3.6–5.6%) [24], and this fact 
could potentially be explained by the inclusion of both 
main and secondary BC diagnosis in the present study. 
The main BC admission code HAR in mainland Por-
tugal was 118.72/105 inhabitants, which is in the range of 
previously reported rates (111.1–140.5/105 inhabitants) 
[47], whereas the HAR for secondary and all BC codes 
were 42.36 and 153.34/105 inhabitants (0.91 admissions/h). 
The HAR for all BC admissions showed an increase over 
the studied period, i.e., from 125.73/105 inhabitants in 
2002 (0.74 admissions/h) to 173.10/105 inhabitants (1.02 
admissions/h) in 2016; this trend is similar to that report-
ed for Spain [47]. 
The increase in BC admission codes was mostly no-
ticed in the last (2009–2016) versus the earlier years of the 
analysis (2002–2008) and could reflect changes in the 
hospital billing mindset, the outcome of coding training 
sessions, sub-notification of this disease in the beginning 
of the period of analysis, an increase in the incidence of 
this cancer in the Portuguese population, or improved 
survival among these patients [3, 22, 23, 48–50]. Addi-
tionally, some heterogeneous coding patterns were de-
tected throughout the country in terms of all and second-
ary admission codes. These regional asymmetries should 
be further evaluated to determine local needs for further 
health investment or the need for changes in BC patients’ 
follow-up plan.
The mainland main BC code HAR showed a flat pe-
riod from 2002 to 2007, increasing from 117.51/105 in-
habitants in 2008 to 126.34/105 inhabitants in 2016 (the 
maximum HAR in 2013 reached: 143.97/105 inhabitants) 
(online suppl. Table 3). Additionally, the temporal varia-
tion in hospitalizations of patients with main BC admis-
sion codes was +3.109%/year, which is similar to the 
growth of incidence reported in a previous study con-




































































Fig. 1. Spatial variations in temporal trend clusters of main BC code HAR in mainland Portugal (n = 278) between 
2002 and 2016 presenting statistical significance (p < 0.05).
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parallelism could point to a link between BC incidence 
and hospitalizations with BC as a main admission code or 
a good referral of newly diagnosed cases to surgical treat-
ment (which corresponded to 85.5% of the cases with a 
main BC admission code), a link that could potentially be 
explored to complement cancer registries data. This 
growth in BC-HAR is concordant with the published data 
on this topic [3, 22–24] and could reflect an increased in-
cidence and prevalence of BC in this population, high-
lighting the need to prepare healthcare systems to handle 
the higher demand by cancer patients, or the presence of 
incomplete data in the database on the earlier years of the 
studied period due to limitations in the coding field. 
Most of the counties identified as presenting the high-
est HAR in each of the analyzed years corresponded to 
small rural populations with a low number of inhabitants 
(small numbers). The only exception detected (Coimbra 
for 2002–2016) could potentially be explained by the re-
ferral of patients to the specialized oncology center in Co-
imbra; however, further analyses are of paramount rele-
vance to detect any overuse of hospital services by BC 
patients in these areas or identify the reasons for the high-
er prevalence of BC in this county.
The spatiotemporal clusters identified for main BC ad-
mission codes, located in the northwest (clusters A and 
B) and southwest coasts of the country (clusters C and D), 
showed an RR ranging from 1.37 to 1.11, with the highest 
RR being reported in the north of the country. The 2 
southern clusters (clusters C and D) align geographically 
and temporally with previously published data on areas 
with a high BC incidence in 2009 [22], further supporting 
the link between incidence and HAR in BC patients.
The spatial variations in the temporal trend analysis of 
main BC admission code hospitalizations identified 3 
clusters for which the behavior of HAR over time was sta-
tistically different from the country trend (Table 4). 
Whereas the HAR in the rest of the country slowly in-
creased over the studied period (∼170–180/105 inhabit-
ants), the HAR in cluster E doubled in 2008, growing then 
more slowly toward the national trend. On the other hand, 
clusters F and G showed high variations in BC-HAR over 
the studied period (Fig.  1). The differential behavior of 
these regions could have to do with coding variances in 
the hospitals of different regions, population differences 
in terms of BC incidence/prevalence, or differential needs 
for care of the populations of these regions.
When looking into the 3 clusters identified in the spatial 
variations in temporal trend analysis of the main BC ad-
mission codes, cluster F presented a higher median age at 
admission than the rest of the mainland, whereas clusters 
E and G shower a significantly lower median age at admis-
sion. This discrepancy in the age at admission could be the 
result of an older resident population in the cluster F coun-
ty (≤64 years: 83, 79, and 63% in clusters E, G, and F, re-
spectively). The LOS was significantly different between 
these 3 clusters and the rest of the country, with clusters F 
and G showing the highest median (8 and 6 days, respec-
tively). Cluster E presented the highest relative number of 
surgical admissions, which could potentially be explained 
by the hospitalization of more newly diagnosed BC cases 
at the oncologic center located in that area. Cluster F 
showed the highest lethality rate among BC admissions 
(6.38%), and cluster E and the rest of the country showed 
concordant results on this outcome for the respective geo-
graphic areas (3.4–6.5 and 5.2–8.7%, respectively) [24]. 
This increased lethality can be a result of numerous factors 
such as the older population or the rural nature of the 
county, which could potentially decrease healthcare access 
and lead to a later diagnosis of these patients. The 3 clusters 
also showed divergences in their baseline demographics, 
with most patients in cluster E being from urban areas, 
whereas the ones in cluster F were from a rural setting. 
These differences are outside of the scope of this study but 
could eventually impact the patient’s outcome during hos-
pitalizations or even point to the potential cancer care or-
ganizational differences in the different areas of the coun-
try. Therefore, further studies are needed to assess these 
regional asymmetries, i.e., in terms of the characteristics of 
the hospitalization (admission for cancer therapies such as 
radiation or chemotherapy, number of comorbidities, or 
presence of complications).
The spatiotemporal and the spatial variation in tempo-
ral trend clusters also showed some similarities, with clus-
ters A and E almost perfectly overlapping geographically. 
These resemblances point to a disparity in the behavior of 
BC hospitalizations in these areas, translated into tempo-
ral trends that are statistically different from the national 
trend, and reinforce the complementary of these statisti-
cal methods in the detection of spatial and temporal crit-
ic areas/periods. Further studies should be carried out to 
clarify these findings and to assess whether the growing 
BC-HAR trends persisted after the studied period, espe-
cially considering that the high BC-HAR spatiotemporal 
clusters were detected in the later years of the analysis. 
Additionally, the BC incidence and mortality rate should 
be analyzed together with the HAR in this population to 
get a more accurate picture of the reality of this malig-
nancy in Portugal.
This study has some limitations, such as the impossi-
bility of determining repeated admissions of the same pa-
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tient over the studied period, the changes in the geo-
graphic boundaries of regions (different geographical ad-
ministrative organization) during the analyzed years, and 
the possibility of incomplete information or coding er-
rors in some registries. Additionally, as coding of admis-
sions is conducted at a local level, some regional differ-
ences could be the result of local coding guidance. More-
over, the occurrence of training coding sessions could 
have influenced the spatial and temporal distribution of 
BC hospitalizations in this period; therefore, the differ-
ences identified could result in increased notification 
rather than an actual growth of HAR among these pa-
tients. The increase in the number of diagnosis fields per 
hospitalization in 2011 and the growing focus on hospital 
costs could also have led to a more complete record of 
admission codes over time (hence the focus on the main 
admission codes in the present study).
Portuguese women have shown a growing BC-HAR; 
however, the trend for this increase varied according to 
the area of residence and the definition of BC hospital 
admission as a main or secondary admission code. The 
reasoning behind these different patterns could be related 
to the distribution of BC cases in the country, regional BC 
management guidelines, or the lack of health structures 
in some areas that can follow-up these patients outside of 
the hospital context [22, 48]. Altogether, these data sup-
port the uneven distribution of BC hospitalizations re-
ported previously in different Portuguese regions [24] 
and the need for further studies on this topic to evaluate 
potential inequalities in BC care.
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